Raymond James Financial Services Advisors Inc. lessened its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 45.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,224 shares of the biotechnology company's stock after selling 6,766 shares during the period. Raymond James Financial Services Advisors Inc.'s holdings in Ascendis Pharma A/S were worth $1,036,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Wellington Management Group LLP lifted its stake in shares of Ascendis Pharma A/S by 14.6% in the 1st quarter. Wellington Management Group LLP now owns 4,665,579 shares of the biotechnology company's stock valued at $547,552,000 after acquiring an additional 594,855 shares during the last quarter. Westfield Capital Management Co. LP raised its position in Ascendis Pharma A/S by 4.7% during the 3rd quarter. Westfield Capital Management Co. LP now owns 3,802,177 shares of the biotechnology company's stock valued at $356,036,000 after purchasing an additional 170,465 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its position in Ascendis Pharma A/S by 39.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,828,267 shares of the biotechnology company's stock valued at $345,417,000 after purchasing an additional 796,087 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Ascendis Pharma A/S by 3,024.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,754,458 shares of the biotechnology company's stock valued at $205,903,000 after purchasing an additional 1,698,302 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in Ascendis Pharma A/S by 16.3% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,264,470 shares of the biotechnology company's stock valued at $118,405,000 after purchasing an additional 176,948 shares during the last quarter.
Analysts Set New Price Targets
A number of research analysts have commented on ASND shares. StockNews.com raised Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Monday, December 25th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $173.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, April 1st. Wells Fargo & Company increased their target price on Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an "overweight" rating in a research report on Friday, March 15th. Wedbush increased their target price on Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an "outperform" rating in a research report on Thursday, February 8th. Finally, Jefferies Financial Group initiated coverage on Ascendis Pharma A/S in a research report on Wednesday, December 20th. They issued a "buy" rating and a $150.00 target price for the company. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Ascendis Pharma A/S currently has a consensus rating of "Moderate Buy" and an average target price of $173.25.
Read Our Latest Stock Report on Ascendis Pharma A/S
Ascendis Pharma A/S Trading Down 0.6 %
ASND traded down $0.81 during trading on Monday, hitting $145.23. 379,111 shares of the company's stock traded hands, compared to its average volume of 378,047. The company's 50 day simple moving average is $149.10 and its two-hundred day simple moving average is $123.28. Ascendis Pharma A/S has a 12-month low of $66.03 and a 12-month high of $161.00. The stock has a market capitalization of $8.46 billion, a price-to-earnings ratio of -15.70 and a beta of 0.50.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.15) by $0.49. The firm had revenue of $148.62 million for the quarter, compared to the consensus estimate of $97.02 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. On average, equities analysts expect that Ascendis Pharma A/S will post -4.18 EPS for the current year.
Ascendis Pharma A/S Profile
(
Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Further Reading
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
